ClearPoint Neuro
CLPT
69 hedge funds and large institutions have $97.5M invested in ClearPoint Neuro in 2021 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 24 increasing their positions, 19 reducing their positions, and 17 closing their positions.
45% more call options, than puts
Call options by funds: $4.34M | Put options by funds: $2.99M
26% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 19
4% less capital invested
Capital invested by funds: $102M → $97.5M (-$4.58M)
1.29% less ownership
Funds ownership: 25.82% → 24.53% (-1.3%)
9% less funds holding
Funds holding: 76 → 69 (-7)
35% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 17
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
+$9.82M |
| 2 |
GPC
Guardian Point Capital
Charlottesville,
Virginia
|
+$4.31M |
| 3 |
FAM
Fred Alger Management
New York
|
+$3.57M |
| 4 |
Goldman Sachs
New York
|
+$1.21M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$871K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PGM
Parian Global Management
Pound Ridge,
New York
|
-$9.85M |
| 2 |
KC
Kepos Capital
New York
|
-$1.41M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$1.08M |
| 4 |
Millennium Management
New York
|
-$974K |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$921K |
CLPT Hedge Fund Activity: Q3 2021 in Review
69 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in ClearPoint Neuro (CLPT) for Q3 2021, worth a combined $97.5M — down 4.5% from $102M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of CLPT and 11 opened new positions — a net loss of 6 holders — while 19 trimmed existing stakes and 24 added.
The largest buyer was Royce & Associates, adding an estimated $9.82M. The largest seller was Parian Global Management, cutting an estimated $9.85M.
- 69 institutional investors held ClearPoint Neuro (CLPT) as of Q3 2021, down from 76 in Q2 2021.
- Funds reported $97.5M of ClearPoint Neuro stock for Q3 2021, down 4.5% quarter-over-quarter.
- 11 funds opened new ClearPoint Neuro positions in Q3 2021 and 17 closed out, a net change of -6 holders.
- The largest ClearPoint Neuro buyer in Q3 2021 was Royce & Associates, an estimated $9.82M added.
- The largest ClearPoint Neuro seller in Q3 2021 was Parian Global Management, an estimated $9.85M sold.
Based on aggregated 13F filings for Q3 2021.